Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963720 | 0.90 | KDM4E (0.56) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL3960495 | 0.86 | ESR2 (0.53) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL28486759 | 0.84 | PTGS1 (0.49) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL2030055 | 0.79 | ESR2 (0.51) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL572237 | 0.78 | ALOX12 (0.52) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL14781369 | 0.75 | KMT2A (0.82) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL14774726 | 0.75 | KMT2A (0.82) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL14774778 | 0.75 | KMT2A (0.82) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL572086 | 0.73 | KMT2A (0.41) | ESR1ESR2KMT2AMEN1CYP3A4 | |
| SCHEMBL31547349 | 0.73 | MAPT (0.46) | ESR1ESR2KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-2898923-A2 | Isoflavones for regulating sirtuin gene expression | Nestec S.A. (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8742141-B2 | Inhibition and treatment of prostate cancer metastasis | NORTHWESTERN UNIVERSITY (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2699095-A2 | METHODS AND COMPOSITIONS SUITABLE FOR PREVENTING AND TREATING HYPERLEPTINEMIA | Nestec S.A. (CH) | 2014-02-26 | — | — | EP | disclosed |
| EP-2696692-A1 | METHODS FOR REGULATING SIRTUIN GENE EXPRESSION | Nestec S.A. (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-20140037583-A1 | METHODS AND COMPOSITIONS SUITABLE FOR PREVENTING AND TREATING HYPERLEPTINEMIA | PAN YUANLONG (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039047-A1 | METHODS FOR REGULATING SIRTUIN GENE EXPRESSION | PAN YUANLONG (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130296582-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| US-8481760-B2 | Inhibition and treatment of prostate cancer metastasis | NORTHWESTERN UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2012145281-A2 | METHODS AND COMPOSITIONS SUITABLE FOR PREVENTING AND TREATING HYPERLEPTINEMIA | NESTEC S.A. (CH) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012141876-A1 | METHODS FOR REGULATING SIRTUIN GENE EXPRESSION | NESTEC S.A. (CH) | 2012-10-18 | — | — | WO | disclosed |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-06-03 | — | — | US | disclosed |
| US-7462478-B2 | isolated from licorice; catalyzes a dehydration reaction of 2-hydroxy hisoflavanone | NIHON UNIVERSITY (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20070050865-A1 | Polynucleotide encoding 2-hydorxyisoflavanone dehydratase and application of the same | NIHON UNIVERSITY (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296582-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | ESR1 872/4885ESR2 1564/4885KMT2A 772/4885 |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | ESR1 872/4885ESR2 1564/4885KMT2A 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.